
Copenhagen-based biotech startup Commit Biologics has raised €54 million ($60 million) in a Seed funding round. The company is developing new treatments for cancer and autoimmune diseases.
The company will use the new funding to advance its first drug candidate and bring it closer to clinical trials. This will help Commit Biologics move forward with the development of its potential treatments.
The final funding round was led by Ackermans & van Haaren. New investors AbbVie Ventures and M Ventures also participated, along with existing investors Bioqube Ventures, Korys and Novo Holdings.
“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy,” says Dr. Thomas L. F. Montgomery Andresen, CEO of Commit Biologics.
Charlotte Kremers, Principal at M Ventures, says: “Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.”
Founded in Copenhagen in 2021, Commit Biologics is developing a new type of immunotherapy that uses the body’s natural immune system to fight diseases. The company is focusing on a part of the immune system called the complement system, which helps the body identify and destroy harmful cells.
The company has developed its own technology, called the Bispecific Complement Engager (BiCE) platform. This technology helps the immune system recognise and destroy diseased cells, including cancer cells. It works by bringing a protein called C1q directly to these cells, allowing the complement system to attack them. Unlike some other immunotherapy treatments, this approach does not depend on T cells.
Commit Biologics has built its technology on more than 30 years of complement system research at Aarhus University. After years of research and development, the company created the BiCE platform and developed its first potential drug candidate, which is now moving towards clinical trials.
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren, adds: “We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realise the full potential of the BiCE platform.”
The funding will help Commit Biologics complete the required studies and prepare the regulatory application needed to begin clinical trials for COM002, its first drug candidate, which the company announced last week.